Bruker stock gains 3.47 percent versus Xetra close at EUR 50.41

Published on 10/20/2026 at 21:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan set Neutral on October 14, 2026 at USD 60.00. Bruker stock stands at EUR 50.41 on October 20, 2026, up 3.47 percent versus Xetra close.

Bruker rises 3.47 percent

JPMorgan set a Neutral rating and kept its USD 60.00 target on October 14, 2026.
Second-quarter 2026 revenue rose 5.20 percent to USD 838.50 million.
Bruker stock costs EUR 50.41 at Lang & Schwarz on October 20, 2026 at 9:03 p.m. CEST, 3.47 percent above the Xetra close of October 20, 2026.
MarketBeat estimated November 2, 2026 for the third-quarter 2026 results.

BRKR, US1167941087, Illustration mit AI erstellt.

Bruker stock (ISIN US1167941087) gained 3.47 percent against the Xetra close as the euro quotation reached EUR 50.41 after the Xetra session on October 20, 2026. JPMorgan had downgraded Bruker to Neutral from Overweight while keeping its USD 60.00 target on October 14, 2026, according to Markets Insider. Bruker was trading at EUR 50.41 at Lang & Schwarz on October 20, 2026 at 9:03 p.m. CEST, 3.47 percent above the Xetra close of October 20, 2026 at EUR 48.72.

JPMorgan sees a cautious setup

JPMorgan cited Bruker's lower relative exposure to biotech tools and higher exposure to academic and government markets as reasons for its more cautious stance. The USD 60.00 target sits 5.43 percent above the Nasdaq quote of USD 56.89 at the latest finance snapshot on October 20, 2026, using the same currency for the comparison.

Second-quarter revenue reached USD 838.50 million

Bruker's second-quarter 2026 revenue increased 5.20 percent year over year to USD 838.50 million, while the company recorded a net loss of USD 62.90 million. The period figures come from Simply Wall St. Bruker also retained adjusted earnings guidance of USD 2.10 to USD 2.15 per share for fiscal year 2026, according to Zacks.

Stock remains below its yearly high

The Nasdaq quote was USD 56.89 on October 20, 2026, while the 52-week range was USD 32.37 to USD 66.98. The current USD quote was 15.06 percent below the high and 75.75 percent above the low. Bruker's market capitalization was USD 8.7 billion and its trading volume was 723,915 shares at the latest quote.

What dates matter next?

MarketBeat estimated November 2, 2026 for Bruker's third-quarter 2026 results, before the market opens, in its earnings calendar. The date is a schedule rather than a reported result. The next scheduled payment date was October 7, 2026 for the company's USD 0.05 quarterly dividend, as listed in the company coverage reviewed by Simply Wall St.

Comparison with peers

Bruker: up 3.47 percent, USD 8.7 billion market capitalization. Thermo Fisher Scientific (NYSE, USD): up 1.79 percent, P/E 37.17, USD 255.7 billion market capitalization. Danaher (NYSE, USD): down 0.23 percent, P/E 39.74, USD 157.4 billion market capitalization.

Price and dates at a glance

The main contrast for investors is between Bruker's 5.20 percent second-quarter revenue growth and its USD 62.90 million net loss in the same period. The stock's euro quotation was EUR 50.41 at Lang & Schwarz on October 20, 2026 at 9:03 p.m. CEST, 3.47 percent above the Xetra close of October 20, 2026 at EUR 48.72. The further course of trading is shown by the continuously updated real-time quote of Bruker stock.